patents 101- Patentability Flashcards
Definition of Patentable Subject Matter
The U.S. patent law identifies patentable subject matter as “any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof.” Meanwhile, In Israel, an invention may be a product or a process in any technological field, which is new, involves an inventive step, and is useful.
Exclusions from Patentability:
In the U.S., laws of nature, natural phenomena, and abstract ideas are not patentable. In Israel, scientific theories, mathematical formulas, ways of performing mental acts, methods of doing business, and computer programs are generally not considered inventions. However, a mathematical formula or computer program that has a practical application producing a useful, concrete, and tangible result can be patented in Israel.
Business Methods and Software Patents:
The U.S. and Israel also handle business method and software patents differently. While the U.S. allows business methods and software to be patented if they meet certain criteria (such as being tied to a particular machine or apparatus, or transforming a particular article into a different state or thing), Israeli patent law generally excludes business methods and computer programs from patentability, unless they produce a “technical effect” and have a practical application.
Example:
Amazon’s “1-Click” patent, granted in the U.S., streamlines online purchases by allowing single-click transactions using stored customer information.
Israel:
In contrast, the same “1-Click” method might not be granted a patent in Israel, as it could be seen as a business method, which is generally non-patentable. However, if it demonstrated a technical effect beyond typical program-computer interactions, it might be considered patentable.
What’s the patentability of software in the U.S. vs ROW?
In the U.S., software can be patented if it’s applied to a particular machine or process. In much of the rest of the world (ROW), software as such is not patentable, but if it has a technical effect, it may be patentable.
example:
U.S.: Google’s PageRank algorithm. ROW: European Patent Office (EPO) requires a technical character, like a new method of compressing video data.
How does patentability of business methods differ between the U.S. and ROW?
In the U.S., business methods are patentable if they are tied to a specific machine or if they transform an article into a different state or thing. In ROW, business methods are generally not patentable.
example:
U.S.: Amazon’s “1-Click” purchase. ROW: EPO does not allow patenting of methods for doing business as such.
What about patenting isolates of nature in the U.S. vs ROW?
In the U.S., naturally occurring substances are not patentable. In ROW, isolates of nature can be patented if isolated from their natural environment and prepared or processed in an artificial way.
example:
U.S.: No patent for isolated DNA sequences. ROW: Some jurisdictions allowed patenting of isolated natural substances like the BRCA1 gene.
How are diagnostic methods treated in the U.S. & AU vs. ROW?
In the U.S. and Australia, diagnostic methods are patentable. In ROW, the situation is more complex. In some countries, they can be patented, while in others, they cannot.
example:
U.S. & AU: Methods of diagnosing diseases like cancer could be patented. ROW: EPO doesn’t allow patenting of diagnostic methods practiced on the human or animal body.
What about methods of treating the human body?
In the European Patent Office (EPO), methods for treatment of the human or animal body by therapy or surgery are not patentable. In ROW, treatment methods may be patentable depending on local laws.
example:
EPO: No patents for surgical methods. ROW: In the U.S., methods of treatment like a unique surgical procedure could be patented.
How is patenting stem cells viewed in the U.S. vs. Israel (IL)?
In the U.S., human embryonic stem cells can be patented if they are not naturally occurring. In Israel, the patentability of human embryonic stem cells is a gray area and depends on ethical considerations and the specific context.
U.S.: The Wisconsin Alumni Research Foundation patented a method to isolate and propagate human embryonic stem cells. IL: Ethical guidelines affect decisions on patenting stem cell research.
How does patentability of organisms differ between the U.S., EPO, and China (CN)?
In the U.S., genetically modified organisms can be patented. In the EPO, they can be patented if the technical feasibility of the invention is not confined to a specific plant or animal variety. In China, animal and plant varieties cannot be patented, but micro-organisms can.
U.S.: Monsanto patents on genetically modified crops. EPO: Patents on genetically modified organisms allowed, but not on specific animal/plant varieties. CN: No patents for animal/plant varieties but micro-organisms can be patented.
What’s the stance on patenting plants?
United States (US): Under the Plant Patent Act, certain types of plants can be patented. This includes asexually reproduced plants that are new, distinct, and have not been sold or disclosed for more than one year.
European Patent Office (EPO): The EPO allows for the protection of plant varieties under the Plant Breeders’ Rights Law rather than patenting. Plant varieties can be protected if they are novel, distinct, uniform, and stable.
China (CN): Plant varieties can be protected under the Plant Breeder’s Rights Act in China. The protection includes novel, distinct, uniform, and stable plant varieties.
methods of generating plants
United States (US): Methods involving traditional breeding can be patented in the US. However, methods involving biological processes for obtaining plants are generally not patentable.
European Patent Office (EPO): Essentially biological processes for the production of plants are not patentable according to the EPO’s interpretation.
China (CN): Methods for breeding plants can be patented in China if they meet the requirements of novelty, inventive step, and industrial applicability.
Novelty
Novelty refers to the requirement that an invention must be new or not publicly disclosed prior to the filing of a patent application. It means that the invention should not have been disclosed in any form, such as through prior publications, public demonstrations, or public use. The invention must be a fresh contribution to the existing knowledge in the field.
mere general reference or abstract discussion of an idea or concept without specific technical details or enabling information would not necessarily invalidate the novelty of an invention. The disclosure must be sufficiently detailed and specific to anticipate or enable the invention.
Inventive Step (Non-obviousness):
Inventive step, also known as non-obviousness, evaluates whether the invention would have been obvious to a person skilled in the relevant field. It means that the invention must not be an obvious combination or modification of existing knowledge or technology. The invention should involve an inventive leap or an unexpected solution to a technical problem.
Industrial Applicability (Utility):
Industrial applicability or utility requires that the invention has a practical use or application and can be made or used in some form of industry or field of technology. The invention should serve a beneficial purpose and be capable of being produced or utilized.
Enablement and Sufficient Disclosure:
Enablement and sufficient disclosure refer to the requirement that the patent application must provide enough information for a person skilled in the field to reproduce or implement the invention without undue experimentation. The application should describe the invention in sufficient detail, including its technical features, steps, components, or formulas, so that others can understand and practice the invention based on the information provided.